Keyphrases
Curcumin
93%
Nanocurcumin
52%
Cisplatin
48%
Doxorubicin
48%
α-mangostin
47%
MRNA Expression
43%
Drug Transporters
40%
Indonesia
39%
Indonesian
33%
Leukemia Patients
32%
MCF-7
29%
Breast Cancer Cells
29%
Hepatic Stellate Cells
28%
In Vitro Study
28%
Triple-negative Breast Cancer Cells
27%
Primaquine
27%
Transmembrane
26%
Androgens
26%
Meta-analysis
26%
Prostate
26%
Rat Model
26%
Antioxidant System
26%
Cell Viability
25%
Sorafenib
22%
Systematic Meta-analysis
22%
Insulin Resistance
21%
Human Breast Cancer Stem Cells
21%
Endoxifen
21%
Kidney
21%
Clinical Trials
20%
Chronic Myeloid Leukemia
20%
Multidrug Resistance Protein 1 (MDR1)
20%
Epithelial-mesenchymal Transition
19%
Plasma Concentration
18%
Oxidative Stress
18%
Ovarian Cancer
18%
Oxidative Stress Markers
17%
Cisplatin-induced
17%
Anticancer Activity
17%
Universitas Indonesia
17%
P-glycoprotein (P-gp)
17%
Pharmacokinetic Profile
17%
Imatinib
17%
MCF-7 Cells
16%
Cisplatin Nephrotoxicity
16%
Confidence Interval
16%
Sprague-Dawley Rats
16%
COVID-19
16%
Quercetin
15%
Phaleria Macrocarpa
15%
Pharmacology, Toxicology and Pharmaceutical Science
Curcumin
100%
Breast Cancer
71%
Cisplatin
67%
Doxorubicin
60%
Malignant Neoplasm
36%
Antioxidant
34%
Effusion
29%
Sorafenib
27%
Liver Fibrosis
27%
Tamoxifen
27%
Primaquine
27%
Cell Viability
23%
Sprague Dawley Rat
22%
Clinical Trial
22%
Rat Model
21%
Triple Negative Breast Cancer
21%
Insulin Resistance
21%
Disease
21%
Nephrotoxicity
20%
Endoxifen
20%
P-Glycoprotein
19%
ABCG2
19%
Ovary Cancer
19%
Andrographolide
17%
Cardiotoxicity
17%
Non Insulin Dependent Diabetes Mellitus
17%
Adverse Event
17%
Pharmacokinetics
16%
Imatinib
16%
Androgen
16%
Chronic Myeloid Leukemia
16%
Ritonavir
15%
Moringa oleifera
15%
Radiosensitizing Agent
15%
Quercetin
15%
Mouse Model
15%
Clopidogrel
15%
Liver Cell Carcinoma
15%
Biological Marker
15%
Transcription Factor Nrf2
15%
Nanoparticle
14%
Cross-Sectional Study
14%
Survivin
13%
Transforming Growth Factor
13%
Streptozotocin
13%
Caspase 3
13%
Malonaldehyde
13%
Infection
13%
Normal Human
13%
Acute Lymphoblastic Leukemia
13%